Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04940299
Title Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
Recruitment Recruiting
Gender
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

melanoma

renal pelvis transitional cell carcinoma

lung non-small cell carcinoma

urethra transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Ipilimumab + Nivolumab + Tocilizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.